These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 36986200)
1. Serum and Urinary Soluble α-Klotho as Markers of Kidney and Vascular Impairment. Martín-Vírgala J; Fernández-Villabrille S; Martín-Carro B; Tamargo-Gómez I; Navarro-González JF; Mora-Fernández C; Calleros L; Astudillo-Cortés E; Avello-Llano N; Mariño G; Dusso AS; Alonso-Montes C; Panizo S; Cannata-Andía JB; Naves-Díaz M; Carrillo-López N Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986200 [TBL] [Abstract][Full Text] [Related]
2. Soluble Klotho, a Potential Biomarker of Chronic Kidney Disease-Mineral Bone Disorders Involved in Healthy Ageing: Lights and Shadows. Martín-Vírgala J; Martín-Carro B; Fernández-Villabrille S; Ruiz-Torres MP; Gómez-Alonso C; Rodríguez-García M; Fernández-Martín JL; Alonso-Montes C; Panizo S; Cannata-Andía JB; Naves-Díaz M; Carrillo-López N Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339121 [TBL] [Abstract][Full Text] [Related]
3. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease . Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871 [TBL] [Abstract][Full Text] [Related]
4. Correlation between soluble klotho and chronic kidney disease-mineral and bone disorder in chronic kidney disease: a meta-analysis. Fan Z; Wei X; Zhu X; Yang K; Tian L; Du Y; Yang L Sci Rep; 2024 Feb; 14(1):4477. PubMed ID: 38396063 [TBL] [Abstract][Full Text] [Related]
5. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients. Manou E; Thodis E; Arsos G; Pasadakis P; Panagoutsos S; Papadopoulou D; Papagianni A Kidney Blood Press Res; 2020; 45(6):900-915. PubMed ID: 33040068 [TBL] [Abstract][Full Text] [Related]
6. [Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome]. Hu S; Wang D; Zhang R; Cao Y; Jin H; Mao Y; Wei L; Ren K; Zhang X; Wang Y Nan Fang Yi Ke Da Xue Xue Bao; 2018 Dec; 38(12):1427-1432. PubMed ID: 30613009 [TBL] [Abstract][Full Text] [Related]
7. Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho. Yamada S; Giachelli CM Bone; 2017 Jul; 100():87-93. PubMed ID: 27847254 [TBL] [Abstract][Full Text] [Related]
8. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Seiler S; Rogacev KS; Roth HJ; Shafein P; Emrich I; Neuhaus S; Floege J; Fliser D; Heine GH Clin J Am Soc Nephrol; 2014 Jun; 9(6):1049-58. PubMed ID: 24677555 [TBL] [Abstract][Full Text] [Related]
9. High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease. Carrillo-López N; Panizo S; Alonso-Montes C; Martínez-Arias L; Avello N; Sosa P; Dusso AS; Cannata-Andía JB; Naves-Díaz M Nephrol Dial Transplant; 2019 Jun; 34(6):934-941. PubMed ID: 30189026 [TBL] [Abstract][Full Text] [Related]
10. Soluble αKlotho as a candidate for the biomarker of aging. Koyama D; Sato Y; Aizawa M; Maki T; Kurosawa M; Kuro-o M; Furukawa Y Biochem Biophys Res Commun; 2015 Nov; 467(4):1019-25. PubMed ID: 26462468 [TBL] [Abstract][Full Text] [Related]
12. Structure-function relationships of the soluble form of the antiaging protein Klotho have therapeutic implications for managing kidney disease. Zhong X; Jagarlapudi S; Weng Y; Ly M; Rouse JC; McClure K; Ishino T; Zhang Y; Sousa E; Cohen J; Tzvetkova B; Cote K; Scarcelli JJ; Johnson K; Palandra J; Apgar JR; Yaddanapudi S; Gonzalez-Villalobos RA; Opsahl AC; Lam K; Yao Q; Duan W; Sievers A; Zhou J; Ferguson D; D'Antona A; Zollner R; Zhu HL; Kriz R; Lin L; Clerin V J Biol Chem; 2020 Mar; 295(10):3115-3133. PubMed ID: 32005658 [TBL] [Abstract][Full Text] [Related]
13. Effect of Dietary Phosphorous Restriction on Fibroblast Growth 2 Factor-23 and sKlotho Levels in Patients with Stages 1-2 Chronic Kidney Disease. Saxena A; Sachan T; Gupta A; Kapoor V Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014808 [TBL] [Abstract][Full Text] [Related]
14. Investigation on urinary and serum alpha klotho in dogs with chronic kidney disease. Yi HJ; Lee JB; Lee KP; Oh YI; Song KH; Seo KW BMC Vet Res; 2020 Jul; 16(1):246. PubMed ID: 32677951 [TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Shimamura Y; Hamada K; Inoue K; Ogata K; Ishihara M; Kagawa T; Inoue M; Fujimoto S; Ikebe M; Yuasa K; Yamanaka S; Sugiura T; Terada Y Clin Exp Nephrol; 2012 Oct; 16(5):722-9. PubMed ID: 22457086 [TBL] [Abstract][Full Text] [Related]
16. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study. Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324 [TBL] [Abstract][Full Text] [Related]
17. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097 [TBL] [Abstract][Full Text] [Related]
18. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)]. Omata M; Fukagawa M; Kakuta T Clin Calcium; 2015 May; 25(5):645-53. PubMed ID: 25926567 [TBL] [Abstract][Full Text] [Related]
19. Correlation between Soluble Wang Q; Su W; Shen Z; Wang R Biomed Res Int; 2018; 2018():9481475. PubMed ID: 30159331 [TBL] [Abstract][Full Text] [Related]